Related Experiment Videos
Nebulised morphine for severe interstitial lung disease.
R Polosa1, A Simidchiev, E H Walters
1Istituto Malattie Apparato Respiratorio, University of Catania, Via Passo Gravina 187, Catania, Italy. R.Polosa@soton.ac.uk
The Cochrane Database of Systematic Reviews
|July 26, 2002
Summary
Nebulized morphine did not improve exercise performance or reduce breathlessness in patients with interstitial lung disease (ILD). This study found no confirmation for its use in managing dyspnea in ILD patients.
Area of Science:
- Respiratory Medicine
- Palliative Care
- Clinical Trials
Background:
- Conflicting evidence exists regarding nebulized morphine for dyspnea in chronic lung disease.
- Interstitial lung disease (ILD) significantly impacts quality of life due to breathlessness.
Purpose of the Study:
- To evaluate the efficacy of nebulized morphine in alleviating dyspnea in patients with end-stage interstitial lung disease.
Main Methods:
- Systematic search of RCTs and controlled clinical trials (CCTs) using specific keywords for morphine and ILD subtypes.
- Included adult patients with ILD in an RCT or high-quality CCT comparing nebulized morphine to a control.
- Identified only one small randomized controlled trial (RCT) for analysis.
Main Results:
- Low-dose nebulized morphine (2.5 and 5.0 mg) did not enhance maximal exercise performance in six ILD patients.
- Nebulized morphine administration did not lead to a reduction in exercise-induced dyspnea compared to placebo (normal saline).
Conclusions:
- The single small RCT did not support the hypothesis that nebulized morphine effectively reduces dyspnea in patients with interstitial lung disease.
- Further research may be needed to definitively determine the role of nebulized morphine in ILD symptom management.